Predictive evaluation of quantitative spatial profiling of the tumor microenvironment by multiplex immunofluorescence in recurrent glioblastoma treated with PD-1 inhibitors.
David Cieremans(Columbia University Irving Medical Center), Fábio M. Iwamoto(Columbia University), Ariana Valencia, Shabnam Tangri(Navidea Biopharmaceuticals (United States)), Justin Santos, Naveen Dakappagari(Navidea Biopharmaceuticals (United States)), Christine Vaupel(Navidea Biopharmaceuticals (United States)), Thai H. Tran(Navidea Biopharmaceuticals (United States)), Ju‐Young Kim(Lineage Cell Therapeutics (United States)), Jennifer Bordeaux(Lineage Cell Therapeutics (United States))
Cited by 1
Related Papers
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
|The Lancet Oncology|2017|1.1k
Antibody validation
|BioTechniques|2010|601
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
|Journal of Translational Medicine|2018|540
Linear Motif Atlas for Phosphorylation-Dependent Signaling
|Science Signaling|2008|465